HomeCompareWWRL vs PFE

WWRL vs PFE: Dividend Comparison 2026

WWRL yields 21505.38% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WWRL wins by $107882141815352868864.00M in total portfolio value
10 years
WWRL
WWRL
● Live price
21505.38%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107882141815352868864.00M
Annual income
$106,904,261,402,781,760,000,000,000.00
Full WWRL calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — WWRL vs PFE

📍 WWRL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWWRLPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WWRL + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WWRL pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WWRL
Annual income on $10K today (after 15% tax)
$1,827,956.99/yr
After 10yr DRIP, annual income (after tax)
$90,868,622,192,364,500,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, WWRL beats the other by $90,868,622,192,364,500,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WWRL + PFE for your $10,000?

WWRL: 50%PFE: 50%
100% PFE50/50100% WWRL
Portfolio after 10yr
$53941070907676434432.00M
Annual income
$53,452,130,701,390,880,000,000,000.00/yr
Blended yield
99.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

WWRL
No analyst data
Altman Z
-135.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WWRL buys
0
PFE buys
0
No recent congressional trades found for WWRL or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWWRLPFE
Forward yield21505.38%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$107882141815352868864.00M$49.6K
Annual income after 10y$106,904,261,402,781,760,000,000,000.00$26,258.71
Total dividends collected$107817657762195783680.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WWRL vs PFE ($10,000, DRIP)

YearWWRL PortfolioWWRL Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,161,238$2,150,537.63$9,153$693.39+$2.15MWWRL
2$436,688,493$434,375,969.13$8,593$849.25+$436.68MWWRL
3$82,493,201,274$82,025,944,586.28$8,336$1,066.78+$82493.19MWWRL
4$14,569,778,490,541$14,481,510,765,177.32$8,437$1,384.80+$14569778.48MWWRL
5$2,405,958,319,119,619$2,390,368,656,134,740.00$9,013$1,875.40+$2405958319.11MWWRL
6$371,480,833,454,370,940$368,906,458,052,912,960.00$10,306$2,680.72+$371480833454.36MWWRL
7$53,630,466,141,085,860,000$53,232,981,649,289,680,000.00$12,820$4,101.38+$53630466141085.84MWWRL
8$7,239,827,382,966,988,000,000$7,182,442,784,196,026,000,000.00$17,673$6,826.70+$7239827382966988.00MWWRL
9$913,906,927,636,562,000,000,000$906,160,312,336,787,400,000,000.00$27,543$12,591.86+$913906927636562048.00MWWRL
10$107,882,141,815,352,870,000,000,000$106,904,261,402,781,760,000,000,000.00$49,560$26,258.71+$107882141815352868864.00MWWRL

WWRL vs PFE: Complete Analysis 2026

WWRLStock

World Wireless Communications, Inc. engages in the design and development of wired and wireless telemetry and remote control systems. Its products and services allow data from remote devices to be accessed via a secure, encrypted Internet connection using a standard Web browser in automatic meter reading and facilities management fields. The company operates through the X-traWeb products and Radio product segments. It offers X-Node, a micro-controller, which collects, processes, and transmits information to provide wired or wireless Internet access; and X-Gate product, which serves as a data collecting and transmitting system on a wired or wireless basis through the Internet to a Web and data-hosting server. The company also provides a line of 900 MHz spread spectrum radios, including the 900 SS Hopper, a frequency hopping spread spectrum radio that offers communication in various environments; and 900 SS MicroHopper that provides a smaller form-factor and lower power-consumption for short-range applications. In addition, it offers the 900 SS Direct—either as a direct sequence or frequency-hopping combined transmitter and receiver for transmitting data up to 40 kilometers, line of sight. World Wireless Communications, Inc. also manufactures and sells antennas. The company maintains approximately 80 specialty antennas for use in law enforcement, marine, and custom applications. World Wireless Communications, Inc. is based in Greenwood Village, Colorado.

Full WWRL Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this WWRL vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WWRL vs SCHDWWRL vs JEPIWWRL vs OWWRL vs KOWWRL vs MAINWWRL vs JNJWWRL vs MRKWWRL vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.